An extended pharmacokinetic/pharmacodynamic model describing quantitatively the influence of plasma protein binding, tissue binding, and receptor binding on the potency and time course of action of drugs

Journal of Pharmacokinetics and Biopharmaceutics

Volumn 24, Issue 1, 1996, Pages 45-77

  Proost, Johannes H ^a   Wierda, J Mark K H ^b   Meijer, Dirk K F ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

effect compartment model; neuromuscular blocking agents; onset time; pharmacodynamic modeling; pharmacokinetic modeling; potency; protein binding; receptor onset offset rate; tissue binding

Indexed keywords

VECURONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING SITE; CONTROLLED STUDY; DISSOCIATION CONSTANT; DOSE CALCULATION; DRUG CLEARANCE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; NEUROMUSCULAR BLOCKING; NONHUMAN; PRIORITY JOURNAL;

BLOOD PROTEINS; MODELS, BIOLOGICAL; PHARMACOKINETICS; PROTEIN BINDING;

EID: 0029901938     PISSN: 0090466X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02353510     Document Type: Article

References (29)

1. M. Gibaldi, G. Levy, and H. Weintraub. Drug distribution and pharmacologic effects. Clin. Pharmacol. Ther. 12:734-742 (1971).
2. M. Gibaldi and G. Levy. Dose-dependent decline of pharmacologic effects of drugs with linear pharmacokinetic characteristics. J. Pharm. Sci. 61:567-569 (1972).
3. P. Dusouich, J. Verges, and S. Erill. Plasma protein binding and pharmacological response. Clin. Pharmacokin. 24:435-440 (1993).
4. L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin. Pharmacol. Ther. 25:358-371 (1979).
5. J. H. Proost, J. M. K. H. Wierda, and D. K. F. Meijer. Pharmacokinetic/pharmacodynamic modeling in the development of new short-acting neuromuscular blocking agents. In Measurement and Kinetics of In Vivo Drug Effects - Advances in Simultaneous Pharmacokinetic/Pharmacodynamic Modelling, Center for Bio-Pharmaceutical Sciences, Leiden University, 1990, pp. 50-51.
6. F. Donati and C. Meistelman. A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs. J. Pharmacokin. Biopharm. 19:537-552 (1991).
7. J. Ducharme, F. Varin, and F. Donati. Vecuronium pharmacokinetic/pharmacodynamic modeling with and without a receptor concentration in the effect compartment in anesthetized patients. Drug Invest. 7:74-83 (1994).
8. W. L. Chiou. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site: Implications in pharmacokinetics, pharmacodynamics, toxicology, and therapeutics (Part 1). Clin. Pharmacokin. 17:175-199 (1989).
9. W. L. Chiou. The phenomenon and rationale of marked dependence of drug concentration on blood sampling site: Implications in pharmacokinetics, pharmacodynamics, toxicology, and therapeutics (Part 2). Clin. Pharmacokin. 17:275-290 (1989).
10. T. K. Henthorn, M. J. Avram, and T. C. Krejcie. Intravascular mixing and drug distribution: The concurrent disposition of thiopental and indocyanine green. Clin. Pharmacol. Ther. 45:56-65 (1989).
11. J. Ducharme, F. Varin, D. R. Bevan, and F. Donati. Importance of early blood sampling on vecuronium pharmacokinetic and pharmacodynamic parameters. Clin. Pharmacokin. 24:507-518 (1993).
12. A. F. Bencini, A. H. J. Scaf, Y. J. Sohn, C. Meistelman, A. Lienhart, U. W. Kersten, S. Schwarz, and S. Agoston. Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure. Anesth. Analg. 65:245-251 (1986).
13. W. H. Press, B. P. Flannery, S. A. Teukolsky, and W. T. Vetterling. Numerical Recipes, Cambridge University Press, Cambridge, UK, 1986, pp. 550-560.
14. W. D. M. Paton and D. R. Waud. The margin of safety of neuromuscular transmission. J. Physiol. 191:59-90 (1967).
15. A. A. D'Hollander and C. Delcroix. An analytical pharmacodynamic model for non-depolarizing neuromuscular blocking agents. J. Pharmacokin. Biopharm. 9:27-40 (1981).
16. D. M. Fambrough, D. B. Drachman, and S. Satyamurti. Neuromuscular junction in myasthenia gravis: Decreased acetylcholine receptors. Science 182:293-295 (1973).
17. J. A. J. Martyn, D. A. White, G. A. Gronert, R. S. Jaffe, and J. M. Ward. Up-and-down regulation of skeletal muscle acetylcholine receptors. Anesthesiology 76:822-843 (1992).
18. Y. M. F. Graus and M. H. Debaets. Myasthenia gravis: An autoimmune response against the acetylcholine receptor. Immunol. Res. 12:78-100 (1993).
19. W. S. Leibel, J. A. J. Martyn, S. K. Szyfelbein, and K. W. Miller. Elevated plasma binding cannot account for the burn-related d-tubocurarine hyposensitivity. Anesthesiology. 54:378-382 (1981).
20. P. H. Marathe, J. F. Dwersteg, E. G. Pavlin, R. H. Haschke, D. M. Heimbach, and J. T. Slattery. Effect of thermal injury on the pharmacokinetics and pharmacodynamics of atracurium in humans. Anesthesiology 70:752-755 (1989).
21. C. W. Hogue, J. M. Ward, M. S. Itani, and J. A. J. Martyn. Tolerance and upregulation of acetylcholine receptors follow chronic infusion of d-tubocurarine. J. Appl. Physiol. 72:1326-1331 (1992).
22. A. C. Le Dain, B. W. Madsen, and R. O. Edeson. Kinetics of (+)-tubocurarine blockade at the neuromuscular junction. Br. J. Pharmacol. 103:1607-1613 (1991).
23. J. C. Law Min, I. Bekavac, M. I. Glavinovic, F. Donati, and D. R. Bevan. Iontophoretic study of speed of action of various muscle relaxants. Anesthesiology 77:351-356 (1992).
24. S. Feldman. Biophase binding: Its effect on recovery from non-depolarizing neuromuscular block. Anaesth. Pharmacol. Rev. 1:81-87 (1993).
25. J. L. Pedraz, B. Calvo, J. A. Smithers, and G. A. Thompson. Pharmacokinetic/ pharmacodynamic modeling: Time-dependent protein binding - An alternative interpretation of clockwise and counterclockwise hysteresis. J. Pharm. Sci. 81:232-236 (1992).
26. W. C. Bowman, I. W. Rodger, J. Houston, R. J. Marshall, and I. Mclndewar. Structure: action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat. Anesthesiology 69:57-62 (1988).
27. A. F. Kopman. Pancuronium, gallamine, and d-tubocurarine compared - Is speed of onset inversely related to drug potency. Anesthesiology 70:915-920 (1989).
28. F. Donati. Onset of action of relaxants. Can. J. Anesth. 35:S52-S58 (1988).
29. J. H. Proost and D. K. F. Meijer. Plasma protein and tissue binding in compartmental models: The clearance approach versus the rate constant approach. (submitted).